MoonLake Immunotherapeutics Signs 3-Year Technology Partnership With Komodo Health

MoonLake Immunotherapeutics and Komodo Health recently announced a new technology partnership to help improve treatment for people living with inflammatory skin and joint diseases. The two companies will collaborate to maximize the impact of MoonLake’s nanobody-based therapy in hidradenitis suppurativa (HS) and active psoriatic arthritis (PsA), two underdiagnosed diseases with significant unmet patient needs.

Through this multiyear technology partnership, MoonLake will utilize Komodo’s Healthcare Map and platform technologies to enable data-driven decision making across its clinical operations, medical, marketing, and market access teams. Komodo’s data and technology applications will support MoonLake’s in-depth market research, clinical trial site selection, go-to-market strategies, and patient journey mapping – all aimed at accelerating the development of new treatment options and improving outcomes for patients with inflammatory skin and joint diseases.

Tino Anthamatten, VP Marketing & Market Access & Pricing, MoonLake Immunotherapeutics, said “We need an experienced technology partner that can help accelerate our disease insights for our clinical, medical, and commercial endeavors. Komodo’s data-driven intelligence is expected to be a critical tool as we work towards commercialization and delivering transformative therapies to patients.”

Recent research underscores the challenges life sciences companies face generating data-driven intelligence that can support decision-making across the product life cycle. On average, it takes seven months to identify and integrate data sources before teams can even begin to generate insights.

Using Komodo’s software applications and Healthcare Map, MoonLake was able to identify important findings, presented at its R&D day last month, related to the HS market. The real-world analysis of the US patient population revealed that between 2016 and 2023, 2 million unique patients were diagnosed and treated for HS, not including undiagnosed and untreated patients. The data also revealed that, on average, 240,000 net new patients get diagnosed and treated each year. This data helps to substantiate the prevalence of HS as ~2% as stated in the literature. The real-world insights from Komodo helped validate a future HS market size projected to exceed $10B by 2035. Today, there is a notably low penetration of current biologics (around 3%) and a high dropout rate from these current biologics within the first year (median treatment duration in a real world setting of 11 months). Furthermore, these insights shed light on the challenges of care and that individuals living with HS are being lost in their treatment journey. Over 50-60% of patients are on long-term antibiotics, and many are concurrently prescribed steroids and/or opioids. This real-world perspective substantiates MoonLake’s market size estimates and highlights the need for more effective therapies.

“We are thrilled to support MoonLake’s efforts to advance scientific innovation and gain a deeper understanding of patient journeys and unmet needs for people living with inflammatory diseases,” said Web Sun, President and Co-Founder, Komodo Health. “As MoonLake expects to commence phase 3 trials, we look forward to helping their teams utilize data and analytics to evaluate the market, develop their go-to-market strategy, and most importantly help to quickly bring its Nanobody therapy to market, once approved, for patients who need it most.”

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company unlocking the potential of sonelokimab, a novel investigational Nanobody for the treatment of inflammatory disease, to revolutionize outcomes for patients. Sonelokimab inhibits IL-17A and IL-17F by inhibiting the IL-17A/A, IL-17A/F, and IL-17F/F dimers that drive inflammation. The company’s focus is on inflammatory diseases with a major unmet need, including hidradenitis suppurativa and psoriatic arthritis – conditions affecting millions of people worldwide with a large need for improved treatment options. MoonLake was founded in 2021 and is headquartered in Zug, Switzerland. For more information, visit www.moonlaketx.com.

Komodo Health is a technology platform company creating the new standard for real-world data and analytics by pairing the industry’s most complete view of patient encounters with enterprise software and machine learning that connects the dots between individual patient journeys and large-scale health outcomes. Across Life Sciences, payers, providers, and developers, Komodo helps its customers unearth patient-centric insights at scale — marrying clinical data with advanced algorithms and AI-powered software solutions to inform decision-making, close gaps in care, address disease burden, and help enterprises create a more cost-effective, value-driven healthcare system. For more information, visit Komodohealth.com.